Researchers from a tertiary pulmonary hypertension expert center in Abu Dhabi, United Arab Emirates, conducted a retrospective single-center cohort study (PH RISE-ME) evaluating the real-world effectiveness and safety of sotatercept in adults with pulmonary arterial hypertension already on optimised background therapy.
The findings reveal that adding sotatercept In this cohort was associated with improved right-heart remodeling, NT-proBNP, and risk profile, with acceptable short-term safety. These findings complement trial evidence and provide early regional support for activin pathway inhibition in routine practice.
Patients with pulmonary arterial hypertension in this region tend to be younger and at higher risk than those in other cohorts, and may therefore benefit from treatment intensification and from targeting several disease pathways.
While the study is limited by its retrospective, single-arm design and relatively small sample, it provides early experience from the region and underlines the need for larger prospective multi-centre studies to establish the durability and long-term clinical impact of sotatercept across different patient populations and healthcare settings.
Read more at this link on the Wiley Online LIbrary
Citation
Jabi MA, Sabbour H, Mohamed L, Alsultan S, Almassabi M, Osama M, Abudouleh A, Sondoqah M, Zaki MK, Hesham A, Saleh KM, Haque MUI, Preston I. First Report of Real World Utilization of an Activin Signaling Inhibitor in Patients With Severe Pulmonary Arterial Hypertension in the Middle East PH RISE-ME Study. Pulm Circ. 2026 Oct 22;16(4):e70434. doi: 10.1002/pul2.70434. PMID: 42924171; PMCID: PMC13689535.
Credit: Wiley Online Library